NEW YORK (GenomeWeb) – BioMérieux today reported that its fourth quarter revenues rose 7 percent year over year, driven in large part by an uptick in revenues for its FilmArray molecular diagnostic products.
For the three months ended Dec. 31, BioMérieux reported revenues of €591.5 million ($627.8 million), up from €553.1 million in the prior-year period. Clinical applications revenues rose 9 percent to €474.2 million from €437.1 million in Q4 2015. Within the clinical applications segment, molecular biology revenues increased 47 percent to €99.8 million from €67.9 million in the prior-year period. FilmArray contributed €80 million in the period.
In Q4, immunoassays contributed €124.2 million in revenues, up 4 percent from €119.7 million in Q4 2015. Revenues from the firm's Vidas immunoassays were up more than 6 percent on a like-for-like basis from the prior-year period. Microbiology, the largest sub segment within clinical applications, rose less than 1 percent to €248.0 million from €246.7 million in Q4 2015.
Industrial applications revenues in Q4 grew 2 percent to €104.7 million from €102.4 million in Q4 2015, driven in part by 14 percent revenue growth in the BioFire Defense business segment to €7.9 million.
For the full-year 2016, the firm reported that total revenues rose to €2.10 billion from €1.96 billion in 2015, reflecting organic sales growth of around 10 percent. Reported sales were impacted by a negative currency effect of around €33.0 million, as well as the change in scope resulting primarily from the deconsolidation of the firm's bioTheranostics business as of Jan.1, 2016, BioMérieux said.
For the year, the firm's FilmArray sales contributed €249.0 million in revenues, and BioMérieux said it also experienced a "strong contribution" from the Americas region with revenues of €877.2 million, up 17 percent from €749.3 million in 2015.
Revenues from clinical applications, which include microbiology, immunoassay, molecular biology, and "other" sub-segments, were €1.68 billion, up 8 percent from €1.55 billion in 2015. Microbiology revenues rose 2 percent to €897.3 million from €879.2 million in 2015.
Immunoassay revenues were €451.7 million, up 4 percent, from €435.6 million in 2015. The firm's Vidas immunoassay sales rose around 8 percent on a like-for-like basis over 2015.
Molecular biology revenues rose 43 percent to €322.8 million from €226.2 million in 2015, driven primarily by FilmArray revenues.
Revenues from industrial applications, which include BioFire Defense, Applied Maths, and R&D-related revenues, were €379.9 million, up 5 percent from €362.7 million in the prior year. BioFire Defense revenues were €35.2 million, up 42 percent from €24.8 million in 2015. Applied Maths revenues were €3.8 million, and R&D-related revenues were €6.4 million, down slightly from €6.8 million in the prior year.
BioMérieux said that its installed base was around 86,900 instruments at the end of 2016, up from 84,500 instruments at the end of 2015. Around 5,000 new instruments were installed in 2016, on par with installations in 2015, the firm added.
Separately today, BioMérieux said it had inked an agreement with San Diego-based Banyan Biomarkers, which develops blood tests for diagnosing traumatic brain injuries.